valu usd unless otherwis note
share repres attract valu current level
view yesterday sell ignor two import valu driver
share long term pharmaceut segment perform
balanc sheet pharmaceut growth acceler
new approv expect year earli help mitig
impact gener competit jnj strong balanc sheet
give manag ampl flexibl pursu share buy-back
pharmaceut growth acceler drive strong ww
revenu growth jnj ww revenu y/i organ
cc line estim combin sale
darzalex xarelto jump y/i zytiga growth set anoth
record intern manag
express high degre confid zytiga face gener
competit tremfya strong start alreadi
annual run rate six month launch
medic devic growth improv sequenti manag
believ growth acceler ww segment revenu
y/i organ cc highest organ growth rate
sinc upsid rel ww revenu estim
surgeri product categori advanc gener
off-set miss spine electrophysiolog vision
continu well manag express confid
product introduc calendar year
keep segment path recoveri
revenu ep guidanc previou estim
forecast ww revenu
report organ cc refer organ cc growth
three segment expect particip
drive higher organ growth help new product portfolio
ration non-gaap ep guidanc assum
bp increas pre-tax margin guidanc
incom line item larg number
manag plan reinvest fund similar
occur therebi limit extent margin expans
rais estim new ww revenu estim
prior two reason
increas higher sale estim sever
brand currenc non-gaap ep estim increas
revenu estim medic
devic consum segment impli oper growth
room upsid perform segment
improv manag forecast
price prior trade day market close estimate unless otherwis note
segment revenu growth acceler
pharmaceut segment revenu
y/i organ cc nearli
compar growth rate intern
despit higher level sale eros remicad
price relat combin sale five mega-
darzalex xarelto jump y/i
tremfya approv
europ strong start alreadi annual run
rate six month launch
new product annual peak sale
billion expect win approv within next
month esketamin expect file regulatori
approv breakthrough therapi design
fda could receiv approv earli
apalutamid fda review pdufa date
april initi indic treatment-resist
major depress disord pre-metastat prostat cancer
respect also work line extens sever
could gener million annual sale
franchis good start manag laid
four-prong growth strategi two key brand opsumit
uptravi frequent earlier use combin
regimen pah treatment improv patient respons
extend treatment durat expand usag new
patient segment broaden geograph reach
volum growth rather price increas key
increas slow channel particip continu exert
downward pressur price even absenc
legisl action innov hold key thrive
environ strong track record last
five year bring breakthrough therapi market well
ahead industri averag
bloomberg capit market estim upside/downside/target
arriv price target use sum-of-the-
part sotp price-to-earnings analysi valu three segment
medic devic consum separ
base peer group multipl base case estim
assum mid-single-digit oper growth includ
low-single-digit organ growth exclud
margin expans share buyback price
target impli price-to-earnings multipl ep estim
 lift revenu growth basi point
restructur portfolio ration lead superior
leverag rel base case scenario
pharmaceut price rhetor lead legisl
chang govern negoti price
multipl ep estim y/i
assumpt
aggress eros remicad brand
biosimilar gener competit lack depress
revenu growth neg leverag dent
multipl downsid scenario impli
price-to-earnings multipl y/i ep estim
assumpt
price target base sum-of-the-part sotp analysi target price-to-earnings
multipl base year medic devic consum segment
respect correspond peer group multipl
assign premium multipl segment
higher growth rate compar peer pharmaceut segment contribut toward
price target medic devic consum price target impli blend price-to-earnings
multipl ep estim y/i basi outperform
rate share
risk rate price target
face risk typic global diversifi healthcar compani includ
slump navig fda may impedi price target rate
johnson johnson one largest diversifi healthcar busi
world oper compani encompass broad rang product across
healthcar field compani world-wide busi divid three main segment
medic devic diagnost sale consum
